134 related articles for article (PubMed ID: 8447160)
1. Quantification of pertussis toxin, filamentous haemagglutinin, 69 kDa outer membrane protein, agglutinogens 2 and 3 and lipopolysaccharide in the Danish whole-cell pertussis vaccine.
Ibsen PH; Petersen JW; Heron I
Vaccine; 1993; 11(3):318-22. PubMed ID: 8447160
[TBL] [Abstract][Full Text] [Related]
2. Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA.
Westdijk J; van den Ijssel J; Thalen M; Beuvery C; Jiskoot W
J Immunoassay; 1997 Aug; 18(3):267-84. PubMed ID: 9257265
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
Podda A; Nencioni L; Marsili I; Peppoloni S; Volpini G; Donati D; Di Tommaso A; De Magistris MT; Rappuoli R
Vaccine; 1991 Oct; 9(10):741-5. PubMed ID: 1759492
[TBL] [Abstract][Full Text] [Related]
4. Does whole-cell pertussis vaccine protect black South African infants? Assessment of post-vaccination events and antibody responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3.
Ramkissoon A; Coovadia HM; Loening WE; Ndlovana M
S Afr Med J; 1991 Jun; 79(11):645-9. PubMed ID: 1675492
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
[TBL] [Abstract][Full Text] [Related]
6. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
Thomas MG; Ashworth LA; Miller E; Lambert HP
J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
[TBL] [Abstract][Full Text] [Related]
7. Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin.
Blom J; Heron I; Hendley JO
APMIS; 1994 Sep; 102(9):681-9. PubMed ID: 7946271
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
9. Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine.
Petersen JW; Andersen P; Ibsen PH; Capiau C; Wachmann CH; Hasløv K; Heron I
Vaccine; 1993; 11(4):463-72. PubMed ID: 8470432
[TBL] [Abstract][Full Text] [Related]
10. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
11. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
[TBL] [Abstract][Full Text] [Related]
12. Single radial immunodiffusion as a method for the assay of the acellular pertussis vaccine components, pertussis toxoid, filamentous haemagglutinin and pertactin.
Xing DK; Canthaboo C; Corbel MJ; Schild GC
Biologicals; 1998 Sep; 26(3):217-24. PubMed ID: 10208723
[TBL] [Abstract][Full Text] [Related]
13. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
Boros CA; Hanlon M; Gold MS; Roberton DM
Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
[TBL] [Abstract][Full Text] [Related]
14. Collaborative study on a Guinea pig serological method for the assay of acellular pertussis vaccines.
Winsnes R; Sesardic D; Daas A; Terao E; Behr-Gross ME
Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):27-40. PubMed ID: 20144450
[TBL] [Abstract][Full Text] [Related]
15. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
Novotny P; Chubb AP; Cownley K; Charles IG
Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
[TBL] [Abstract][Full Text] [Related]
16. Rabbit nasopharyngeal colonization by Bordetella pertussis: the effects of immunization on clearance and on serum and nasal antibody levels.
Ashworth LA; Fitzgeorge RB; Irons LI; Morgan CP; Robinson A
J Hyg (Lond); 1982 Jun; 88(3):475-86. PubMed ID: 6282959
[TBL] [Abstract][Full Text] [Related]
17. Antigens in whooping cough vaccine and antibody levels induced by vaccination of children.
Ashworth LA; Robinson A; Irons LI; Morgan CP; Isaacs D
Lancet; 1983 Oct; 2(8355):878-81. PubMed ID: 6137697
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine.
Watanabe M; Nagai M; Funaishi K; Endoh M
Vaccine; 2000 Dec; 19(9-10):1199-203. PubMed ID: 11137257
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
20. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
